---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-043764"
form_type: "8-K"
ticker: "AARD"
cik: "0001774857"
company_name: "Aardvark Therapeutics, Inc."
filed_at: "2026-02-10T23:59:59+00:00"
generated_at: "2026-05-16T03:37:49.298943+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aardvark Therapeutics expands Phase 3 HERO trial age eligibility to 7+ years for ARD-101 in PWS

## Summary
- IRB approved amended protocol lowering minimum age from 10 to 7 years for Phase 3 HERO trial evaluating ARD-101.
- Amended protocol submitted to FDA; enrollment on track for topline data in Q3 2026.
- Trial targets 90 patients across US, Australia, Canada, UK, and South Korea.
- Primary endpoint: change in HQ-CT score at 12 weeks; open-label extension offered to completers.

## SEC filing metadata
- accession: 0001193125-26-043764
- form_type: 8-K
- ticker: AARD
- cik: 0001774857
- company_name: Aardvark Therapeutics, Inc.
- filed_at: 2026-02-10T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1774857/000119312526043764/0001193125-26-043764-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1774857/000119312526043764/ck0001774857-20260210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-043764
- JSON: https://secwatch.observer/filing/0001193125-26-043764.json
- Plain text: https://secwatch.observer/filing/0001193125-26-043764.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.